Friday, November 30, 2018, 12-1 pm
Koch Institute Auditorium (76-156)
Joan Brugge, PhD
Louise Foote Pfeiffer Professor of Cell Biology at Harvard Medical School
Director of the Ludwig Center at Harvard Medical School
Dr. Joan Brugge is the Louise Foote Pfeiffer Professor of Cell Biology at Harvard Medical School (HMS) and co-director of the Ludwig Center at Harvard. She joined the HMS faculty as a professor in July 1997. She became chair of the department of Cell Biology in 2004. A graduate of Northwestern University, she did her graduate work at the Baylor College of Medicine, completing her PhD in 1975. She then performed her postdoctoral training at the University of Colorado with Dr. Raymond Erikson. Dr. Brugge has held full professorships at the State University of New York, Stony Brook, and the University of Pennsylvania, where she was also named a Howard Hughes Medical Institute Investigator. She is a founder of the biotechnology company ARIAD, and served as its scientific director from 1992 to 1997.
Dr. Brugge investigates the mechanisms involved in breast and ovarian cancer initiation and progression, as well as the mechanisms involved in cancer therapy resistance. Her laboratory utilizes three dimensional cultures of normal cells and tumor cells to recapitulate the organization of cells in their natural context and to provide important insights relating to the mechanisms by which genes that are altered in breast cancer contribute to tumor formation and progression. She also studies gene alterations that mediate resistance to cancer therapies.
Beginning with the first identification of the viral oncogene Src and the cellular processes regulated by its cellular homologue, Dr. Brugge has made significant contributions to our understanding of the mechanisms involved in tumorigenesis. She later carried out critical investigations into the cellular processes and pathways that are involved in the normal development of breast cells, as well as breast cancer initiation and progression. Her work has highlighted how tumor cells evade homeostatic processes that eliminate early stage tumor cells as they proliferate outside their natural niches, and the role of antioxidants in promoting survival of displaced tumor cells. More recently, she has discovered new insights into cellular responses to cancer therapies that lead to therapy resistance and strategies to overcome resistance.
Dr. Brugge has received several awards recognizing her scientific accomplishments, including the American Cancer Society Research Professorship and Medal of Honor and the Senior Career Recognition Award from the American Society of Cell Biology. She has also been elected to the American Academy of Arts and Sciences, the National Academy of Sciences, and the Institute of Medicine.
The Judith Ann Lippard Memorial Lecture was established in 2014 in memory of Judy Lippard, the wife of Stephen J. Lippard, the Arthur Amos Noyes Professor of Chemistry at MIT. Judy died of endometrial cancer on September 9, 2013. Steve, Josh, and Alex Lippard, together with countless friends, students, and colleagues created the lectureship to honor Judy’s memory and celebrate her remarkable love of life.
The creation of the Judith Ann Lippard Lectureship was inspired by a similar lecture, created in 1974 in memory of Judy’s and Steve’s eldest son, Andrew, who died from a neurological disorder at age 7. Over time, the Andrew Mark Lippard Lecture at Columbia University has become one of the preeminent neurology lectures in the world.
The Judith Ann Lippard Lectureship brings together the most innovative minds in cancer research from a variety of disciplines—biology, chemistry, engineering, clinical medicine—and features individuals whose research has the possibility to change the face of cancer. The Lippard Lecture also unites two extraordinary cancer centers—MIT’s Koch Institute and the Massachusetts General Hospital Cancer Center. In addition to the formal lecture at MIT, the honoree delivers Grand Rounds at MGH, and spends time with trainees, researchers, and physician-scientists at both institutions, thus inspiring the best and brightest young minds to advance cancer therapies.
Tyler Jacks, PhD
Stephen J. Lippard, PhD, ex officio
Jonathan Rosand, MD, MSc
Phillip A. Sharp, PhD
To join the Lippard family in celebrating Judy's life and legacy, please contact Lisa Schwarz, Managing Director of Development, Koch Institute for Integrative Cancer Research at MIT: 617-324-7399; firstname.lastname@example.org, or give online.